

**THE FOLLOWING DRUGS WILL BE REVIEWED AT THE
DRUG UTILIZATION REVIEW BOARD MEETING**

March 17, 2016

Georgia Department of Community Health

This list may change at any time. If a supplemental rebate class is not listed below, the class will be reviewed at the June 16th meeting. In addition, other drugs/classes listed below may be moved for review at the June 16th meeting to be determined by the end of February so please check back for updates. Also, any drugs/classes listed below that the DURB is not able to complete during the March 17th meeting will be reviewed at the June 16th meeting. Manufacturers that presented these drugs at the February Manufacturers' Forum will not need to present the drugs again at the May Manufacturers' Forum. Information on the Manufacturers' Forum can be found at <http://dch.georgia.gov/manufacturers-forum> and <http://dch.georgia.gov/durb-meeting-information>. Please check back frequently for updates.

New Drug Reviews

Corlanor

Entresto

Daklinza

Technivie

Praluent

Repatha

Therapeutic Class Reviews

Atypical Antipsychotics

Antihemophilic Recombinant Factor VIIIs

Antihemophilic Recombinant Factor IXs

Supplemental Rebate Class Reviews

Aminoglycosides for Cystic Fibrosis

Analgesics, Opioids

Opioid Agonists, Partial Agonists

Anaphylaxis Therapy Agents

Androgens, Anabolics

Anticoagulants
Anticonvulsants
Antidementia Agents
Antidepressants
Antihemophilic Products for von Willebrand's disease
Antihyperlipidemics
Antiinflammatory, Antirheumatics
Antivirals, Antiretrovirals
Antivirals, Hepatitis C Agents
Attention Deficit Hyperactivity Disorder (ADHD) Agents
Biologics, Immunomodulators
Biologics, Miscellaneous (Allergen Immunotherapy)
Calcium Regulators, Osteoporosis
Cardiovascular, Angiotensin II Combinations
Cardiovascular, Angiotensin Receptor Blockers
Cardiovascular, Beta Blockers
Corticosteroids
Dermatologics, Antiinflammatory Agents
Dermatologics, Antipsoriatics
Dermatologics, Corticosteroids
Dermatologics, Scabicides/Pediculocides
Digestive Enzymes

Fibromyalgia Agents
Growth Hormones
Hypnotics
Inflammatory Bowel Agents
Irritable Bowel Syndrome (IBS) Agents
Laxatives
Migraine Products
Multiple Sclerosis Agents
Multivitamins, Prenatal
Ophthalmics, Adrenergic Agents
Ophthalmics, Antiallergics
Ophthalmics, Antiinfectives
Ophthalmics, Nonsteroidal Antiinflammatory Drugs
Ophthalmics, Prostaglandins
Ophthalmics, Steroids
Otic Antiinfectives
Phosphate Binders
Platelet Aggregation Inhibitors
Pulmonary Hypertension Agents
Smoking Deterrents
Ulcer Drugs, Antispasmodics
Urinary Antiinfectives

Urinary Antispasmodics

This list may change at any time. If a supplemental rebate class is not listed above, the class will be reviewed at the June 16th meeting. In addition, other drugs/classes listed above may be moved for review at the June 16th meeting to be determined by the end of February so please check back for updates. Also, any drugs/classes listed above that the DURB is not able to complete during the March 17th meeting will be reviewed at the June 16th meeting. Manufacturers that presented these drugs at the February Manufacturers' Forum will not need to present the drugs again at the May Manufacturers' Forum. Information on the Manufacturers' Forum can be found at <http://dch.georgia.gov/manufacturers-forum> and <http://dch.georgia.gov/durb-meeting-information>. Please check back frequently for updates.